Briana Contreras

This once-daily topical treatment is the latest phosphodiesterase-4 (PDE4) inhibitor designed for mild to moderate atopic dermatitis (AD) in children aged 2 to 5 years. The PDUFA target action date of October 13, 2025, is set for its decision on the application.

Although the importance of ongoing education is known for patients, less than half of those with diabetes receive formal instruction on managing their condition.

After receiving the Day 74 letter, which outlines the FDA’s initial assessment of the application, the agency accepted Epioxa for review for efficacy and safety and plans to complete the process by October 20, 2025 under the Prescription Drug User Fee Act (PDUFA).

Obesity rates have spiked over the past few decades, displaying itself a significant crisis.

In this role, Virtell will oversee the strategy, daily operations and expansion of Cigna Healthcare’s Supplemental Health division, which helps customers manage out-of-pocket expenses from serious illnesses or accidents.

Prior to vaccine availability, RSV was a significant cause of illness and hospitalization in older adults in the U.S., particularly those 60 and older.

Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving this drug a priority review and expects to make a decision by June 19, 2025, according to a release.

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S. that helps restore skin color for this condition. It’s also approved to treat mild to moderate atopic dermatitis in patients 12 and older who are not immunocompromised.

Inhalon plans to begin a human challenge for their inhaled antibody therapy study in 2026.

Pemphigus is a rare autoimmune disease that causes painful blisters on the skin and mucous membranes, including the mouth, nose, throat, eyes and genitals.

The respiratory tract’s microbial microflora plays a significant role in determining the severity of RSV infections and the development of these long-term conditions.

Tapinarof, however, offers a potential solution by improving the skin barrier, reducing inflammation and relieving itch without the limitations of traditional treatments.

This follows the company’s recent earnings call, where executives discussed the organization’s growth and future plans, highlighting its focus on serving the best interests of their consumers.

As a non-opioid drug, Journavx can assist patients effectively and without showing signs of being addictive.

The Cigna Group reported today their total revenue of $247.1 billion for 2024, compared with $195.3 billion in 2023. This growth highlights the company’s strong financial results, supported by the success of Evernorth Health Services, new client acquisitions and growth in the specialty drug space.

In this new role, Flaster will lead Cigna Healthcare’s clinical organization, focusing on initiatives to improve customer experience and deliver better health outcomes

As the nation is again under the reigns of a Trump administration and a Republican-led Congress, debates on reducing spending have not affected the public’s feelings on these programs.

This new generic medicine is designed to be a simple, once-daily treatment for children as young as three months old who weigh at least 13 pounds.

TriVerity focuses on whether the patient has an infection and how severely ill they are likely to become.

First discovered in the Netherlands roughly 24 years ago, HMPV belongs to the same viral family as RSV.

One-third of folks with major depressive disorder experience treatment-resistant depression (TRD), a condition that makes it more difficult to be treated by traditional oral antidepressants.

In a phase 2 clinical trial, researchers examined baricitinib and NB-UVB in adults with severe vitiligo in the dermatology departments at 4 hospitals in France between July 2021 and April 2023.

This ranking is based on the reviews of 12,372 consumers who evaluated their experiences with 16 major health insurance brands.

Berge will serve in this role through the end of 2026, marking another milestone in her successful career in healthcare.

Most infants born before December were administered nirsevimab, while those whose mothers reached eligible gestational age after October 25 received maternal RSVpreF.

Study authors Susan D. Reed, MD, MPH, MS, and Erin Dwyer, MPH, both at the University of Washington School of Medicine, attribute some of these different challenges to underlying health disparities.

Out of 6,540 patients involved in a study, 7.1% of those with AD had mobility impairment compared to 3.9% of those without AD.

U.S. approved the RSVpreF vaccine for adults 60 years and older in 2023, recommending it only based on individual’s decisions with their doctors.